BridgeMD
Multicenter study on patient’s ability to independently and safely use of Sildenafil 100 mg for erectile dysfunction.
EU CTIS ID: 2025-522923-81-00
What this study is testing
The primary objective of the study is to assess whether participants using dedicated diagnostic tool can independently make safe decision whether it is appropriate for them to use or not use sildenafil in dose of 100 mg.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Males aged 18 years* and older sexually active and planning to have sexual interactions.
- Signed informed consent to participate in the study prior to commencing study procedures.
- Participants able to understand and follow study procedures.
You likely can't join if
- Lack of reading and writing skills or comprehension in Polish.
- Symptoms of active infection.
- Severe physical or mental disease that might hamper the realization of the trial according to the protocol.
- Unreliability or lack of cooperation
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.